Microbiome restoration - FMT

Phase 1Biologic

Microbiome restoration - FMT is one of 45 biologic programs targeting Microbial Colonization. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Microbial ColonizationRecruiting

Cesarean SectionActive, not recruiting

Microbial ColonizationPhase 1

Recruiting

Cesarean SectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

230 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Preclinical

21 2

Pitocin

RRetrophin

Preclinical

16 3

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

12 4

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

11 5

Dynastat

Pfizer

Preclinical

1 6

Duragesic

CCephalon

Preclinical

6 7

Catapres

Boehringer Ingelheim

Preclinical

4 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

4 9

Nubain

AAultman Health Foundation

Preclinical

3 10

Ancef

BBaxter Healthcare Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Microbial Colonization

NCT06264219

Clinical

Trials by Indication[1]

Microbial Colonization1 trial

"Restoration of the Gut Microbiome After Cesarean Section (RestoreGut)" - A Double-blinded Randomized Placebo-controlled Trial

Recruiting·PProfessor Klaus Bønnelykke·Phase 1·NCT06264219·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Microbiome restoration - FMT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Microbiome restoration - FMT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Microbiome restoration - FMT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Professor Klaus Bønnelykke company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PProfessor Klaus Bønnelykke

Microbiome restoration - FMT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Microbial Colonization1 trial

References

Drug Info

Quick Facts

Related News